Weโre pleased to share another year of strong progress for Diaceutics. Reflecting our continued commitment to driving innovation and delivering value for our pharma and biotech partners moving into 2026.
Here are some key highlights, you can view the full update here: https://lnkd.in/d9pA-QZr
โข Reported revenue expected to be ยฃ38.5m, representing 20% growth and a return to profitability
โข 24% revenue growth on a constant currency basis, in line with analyst consensus estimates
โข Adjusted EBITDA expected to exceed analyst consensus estimates
โข Record order book of at least ยฃ36.8m
โข ARR of at least ยฃ20.3m
โข 12% growth in customer therapeutic brands to 95
โข Second PMx commercialisation partnership signed with an innovative US biotech, underpinning another year of strong commercial growth
โข Additional top 10 global pharma customer confirmed as an enterprise wide engagement partner; consistently working with 18 of the top 20 global pharma companies
โข 25% revenue growth expected in FY 2026
โWith strong commercial momentum, a scalable platform and a proven execution engine, we are confident in delivering another year of high-quality growth and continued value creation in 2026.” Ryan Keeling, CEO.